Lilly Goes All-in on Oral Obesity medications...peptron's 'Smart Depot' Contract Remains Shrouded in Fog.

조선일보

Lean Right

Factuality

Ownership

The technology transfer agreement between Peptron and Eli Lilly for its long-acting drug delivery platform, SmartDepot, is becoming increasingly uncertain. As Lilly focuses its entire company on the launch of its oral obesity treatment, Opogliprone, external collaborations based on injectables appear to be taking a backseat. Lilly recently disclosed in a regulatory filing that it had secured $1.5 billion (approximately 2.15 trillion won) in pre-…